Skip to main content
. 2023 Sep 11;13:15003. doi: 10.1038/s41598-023-40940-w

Figure 3.

Figure 3

Kaplan-Meyer-estimates of CDA events in real-world ocrelizumab cohort. The figure depicts the probability of patients having experienced RAW or PIRA events in the observed cohort over time. CDA shows the probability of at least one of the two having occurred. CDA confirmed disability accumulation; RAW relapse-associated worsening; PIRA progression independent of relapse activity.